PFM Health Sciences’s Neuropace NPCE Stock Holding History

PFM Health Sciences’s Portfolio NPCE Stock Details NPCE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-11,329	Closed	-$175K	–	97
2025 Q4	$175K	Buy	+11,329	New	+$151K	0.02%	77

Other funds holding NPCE

PCH

Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return

SCM

Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

FLAM

First Light Asset Management Edina, Minnesota $1.12B AUM 114.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

DCM

Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return

Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

PFM Health Sciences's NPCE Position: Q1 2026 in Review

PFM Health Sciences sold out of Neuropace (NPCE) in Q1 2026, closing a stake of 11,329 shares — an estimated $175K sold.

PFM Health Sciences first reported a position in NPCE in Q4 2025 and held it in 1 quarter. The position peaked at $175K in Q4 2025. 113 funds tracked by Wall St. Rank hold NPCE as of Q1 2026.

PFM Health Sciences reported no remaining Neuropace position as of Q1 2026 after selling out during the quarter.
PFM Health Sciences sold 11,329 Neuropace shares in Q1 2026, an estimated $175K.
PFM Health Sciences first reported a position in Neuropace in Q4 2025 and held it in 1 quarter.
PFM Health Sciences's Neuropace position peaked at $175K in Q4 2025.
113 funds tracked by Wall St. Rank held Neuropace as of Q1 2026.

Based on PFM Health Sciences's 13F filing for Q1 2026, filed 15 May 2026.